|
|
Vaccine Detail
|
Recombinant Fowlpox-Tyrosinase Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox-Tyrosinase Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007101
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: Tyrosinase
- Tyrosinase
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Melanoma Cancer (NCT00054535). A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, recombinant fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells (NCIT_C2807).
|
| Host Response |
|
|
| References |
NCIT_C2807: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2807]
NCT00054535: [https://clinicaltrials.gov/ct2/show/NCT00054535?term=Recombinant+Fowlpox-Tyrosinase+Vaccine&rank=1]
|
|
